Bharatbook.com : Macro-economic Environment of Chinese Off-patent Drug Market

Research Report of Chinese Off patent Drug Market ( http://www.bharatbook.com/Market-Research-Reports/Research-Report-of-Chinese-Off-patent-Drug-Market.html )The off-patent drugs refer to a kind of copy drug, which have the same dosage, security, strength, quality, performance and intended uses to the commercial name drugs. The legal acquirement of the off-patent drugs approximately concludes two situations: one is the pharmaceutical copy after the patent expiration; the other is the government obtains the production of the off-patent drugs by means of compulsory license in the field of patent drugs relate to the public health.
As the gradual reduction in the approved patent drugs in the market in the world, the development pace of the potent drugs is restrained. The patent expiration of a group of blockbuster pharmaceuticals is just in the corner. The potent of the original researched drugs at market value of 24 billion USD will become invalid in 3 to 5 years. In the next 5 to 10 years, the global off-patent market will usher the overdue pharmaceutical patent business opportunities at the market values of 120 to 150 billion USD, which will bring great business opportunities for the development of the off-patent drugs.
Besides, with the gradual growth of the off-patent drug market, the multinational pharmaceutical giants, such as Pfizer, Sanofi-Aventis and Bayer etc, will involve in the off-patent drug industry.

At present, the scale of Chinese off-patent drug market is about 80 billion Yuan, which still has huge development space in the future. According to the analysis by the experts, the off-patent drugs and the patent drugs are expected to occupy 70% and 30% of the market shares respectively in 5 to 10 years. By 2012, China will become the second largest off-patent drug market in the world at the compound growth rate of 14%.

Although China had carried out the compulsory GMP authentication from 2004, Chinese domestic pharmaceutical manufacturers did not cut down but rise, which had been developed from 3,731 in 2004 to over 4,000 at present. Because Chinese pharmaceutical enterprises are characterized as sparse, random and small, the new drug innovation is in the very beginning phase and most enterprises do not have the capacity of creating new drugs and the proportion of the investments in the new drug research is less than 3%. At present, Chinese local enterprises have brand influences and strong competitiveness; the top pharmaceutical enterprises in large scale are all specialized in the off-patent drug business.

At present, China has more than 4 thousand pharmaceutical enterprises, over 80% of which are the medium and small enterprises. However, America only has about 200 pharmaceutical enterprises. Due to the limited research level, Chinese pharmaceutical enterprises are mainly engaged in the production of the off-patent drugs and the independent renovative pharmaceuticals only account for a small part. Many pharmaceutical enterprises involve in the off-patent drug market, resulting in the fierce industry competitions. Compared with the developed countries, such as America, there is big gap between the production and sales of Chinese off-patent drugs. The average profit is only about 5 to 10 percent in Chinese off-patent drug industry, which reaches 40 to 60 percent in the globe. Among Chinese local pharmaceutical enterprises, there is almost no outstanding enterprise, which even lacks the international market experiences

For vast range of market reports please visit : http://www.bharatbook.com/Market-Research/drugs.html

Or

Contact us at:
Bharat Book Bureau
Tel: 91 22 27578668
Fax: 91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com

Article Source: http://www.articles2use.com - a Rentaccomspain.com company.

Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.

Please Rate this Article

5 out of 54 out of 53 out of 52 out of 51 out of 5 

Not yet Rated